Skip to main content

Fluidigm To Participate In The Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov.

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm's business strategy and financial performance at the following investor event:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be made available on demand Monday, November 22, 2021, at 10:00 a.m. ET. Management will be available Tuesday, November 30, 2021, for virtual one-on-one meetings.

A live webcast of the company's fireside chat and subsequent replay will be available in the  Events & Presentations section of the Fluidigm ® investor website. The webcast will be archived for 90 days following the live presentation.

About Fluidigm Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF ® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit  fluidigm.com.Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Available InformationWe use our website ( fluidigm.com), investor site ( investors.fluidigm.com), corporate Twitter account ( @fluidigm), Facebook page ( facebook.com/Fluidigm), and LinkedIn page ( linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Contact:

Investors:Peter DeNardo415 389 6400 ir@fluidigm.com